Santhera and Catalyst to market DMD drug vamorolone in North America
The agreement covers licensing rights in North America for Duchenne muscular dystrophy and other future indications.
The agreement covers licensing rights in North America for Duchenne muscular dystrophy and other future indications.
What's Your Reaction?
